First data showing preliminary evidence of efficacy were presented at the Retinal Cell and Gene Therapy Innovation Summit organized by the Foundation Fighting Blindness
Zürich, Switzerland, May 3, 2024 First data showing preliminary evidence of efficacy were presented at the Retinal Cell and Gene Therapy Innovation Summit organized by the Foundation Fighting Blindness (May 3rd, Seattle, Washington, US) by Dr. Byron Lam (Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida, USA): “First-in-human study to evaluate safety, […]
Two scientific posters were presented on May 8th at ARVO 2024 in Seattle, Washington, US
Zürich, Switzerland, May 8, 2024 Two scientific posters were presented on May 8th at ARVO 2024 in Seattle, Washington, US, with the respective poster titles: “The promotion of visual function regeneration by intravitreal administration of EA-2353 in animal models of photoreceptor degeneration” “Promotion of structural and visual function improvement by intravitreal administration of EA- 2351 […]
Matthias Steger was invited to present at the Ophthalmology Innovation Summit (OIS) on May 4th, 2024, in Seattle,Washington, US.
Zürich, Switzerland, May 4, 2024 Matthias Steger was invited to present at the Ophthalmology Innovation Summit (OIS) on May 4th, 2024, in Seattle, Washington, US.
Endogena Therapeutics holds investor call and gives update on Retinitis Pigmentosa Clinical Trial
Zürich, Switzerland, February 7, 2024 Listen to a testimonial from one of our principal investigators Dr. Victor Gonzalez.https://www.youtube.com/watch?v=-AaRhoIcK4A
Endogena Therapeutics Secures FDA Green Light for Breakthrough AMD Treatment
San Francisco, USA; Toronto, Canada; Zürich, Switzerland, October 24, 2023 Endogena Therapeutics Inc., a pioneering biotech company dedicated to revolutionizing regenerative medicine, is proud to announce a significant achievement that holds the promise of transforming lives. The U.S. Food and Drug Administration (FDA) has granted clearance for Endogena’s Investigational New Drug (IND) application, opening the […]
Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosa
San Francisco, USA; Toronto, Canada; Zürich, Switzerland, May 4, 2023 Endogena Therapeutics Inc., a clinical-stage biotech company, is pleased to announce that it has completed patient enrollment ahead of schedule in its Phase 1/2a trial of EA-2353 for the treatment of retinitis pigmentosa (RP). With the dose-escalation stage completed in April, the ongoing trial is […]
Endogena Therapeutics Completes Dose Escalation in the Phase 1/2a Clinical Trial of EA-2353 for the Treatment of Retinitis Pigmentosa
San Francisco, USA; Toronto, Canada; Zürich, Switzerland, April 5, 2023 Endogena Therapeutics Inc., a clinical-stage biotech company focused on the development of endogenous regenerative medicines, announced today that the dose-escalation stage of its phase 1/2a study of EA-2353 in retinitis pigmentosa (RP) has been successfully completed. No clinically relevant or dose-limiting adverse events were identified after […]
Endogena Therapeutics Receives US FDA Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosa
San Francisco, USA; Toronto, Canada; Zürich, Switzerland, February 6, 2023 Endogena Therapeutics Inc., a clinical-stage biotech company focused on thedevelopment of endogenous regenerative medicines, announced today that the USFood and Drug Administration (FDA) has designated the investigation of EA-2353 forthe treatment of retinitis pigmentosa (RP) as a Fast Track developmentprogram. Fast Track is a process […]
Sven Weiler joins Endogena as VP Medicinal Chemistry
We are pleased to announce that Sven Weiler has joined our team in Schlieren, Switzerland as Vice President Medicinal Chemistry on August 1st, 2022. “I very much look forward to becoming an integral part of Endogena Therapeutics and to extend my expertise among this passionate group of colleagues. It’s exciting to be joining a company […]
Endogena receives Retina Innovation Award at event showcasing new therapies for eye conditions
July 13th, New York, NY Poignantly crafted from the clearest crystal, the Retina Innovation Award that now claims pride of place in Endogena Therapeutics’ trophy cabinet represents how far the company has come in developing a potential new treatment for people losing their sight because of retinitis pigmenosa (RP). More than 350 international delegates including clinicians, […]